JP2020524143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524143A5 JP2020524143A5 JP2019569758A JP2019569758A JP2020524143A5 JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5 JP 2019569758 A JP2019569758 A JP 2019569758A JP 2019569758 A JP2019569758 A JP 2019569758A JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- bioactive agent
- lipid
- oil
- sorbitan ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 48
- 230000000975 bioactive Effects 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 15
- -1 sorbitan ester Chemical class 0.000 claims 14
- 239000004094 surface-active agent Substances 0.000 claims 14
- 239000002245 particle Substances 0.000 claims 13
- 239000007791 liquid phase Substances 0.000 claims 9
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 claims 8
- 102000038129 antigens Human genes 0.000 claims 8
- 108091007172 antigens Proteins 0.000 claims 8
- 125000002091 cationic group Chemical group 0.000 claims 6
- 230000002209 hydrophobic Effects 0.000 claims 6
- 239000007790 solid phase Substances 0.000 claims 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 4
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 4
- 229940031439 Squalene Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 239000003921 oil Substances 0.000 claims 4
- 235000019198 oils Nutrition 0.000 claims 4
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 239000001294 propane Substances 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- 229940068968 Polysorbate 80 Drugs 0.000 claims 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N Trimyristin Chemical group CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims 2
- 230000000240 adjuvant Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 2
- 239000001587 sorbitan monostearate Substances 0.000 claims 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 229940113164 trimyristin Drugs 0.000 claims 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(Z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M Dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- NFQBIAXADRDUGK-KWXKLSQISA-N N,N-dimethyl-2,3-bis[(9Z,12Z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229940083466 Soybean Lecithin Drugs 0.000 claims 1
- 229940046009 Vitamin E Drugs 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 claims 1
- 239000010775 animal oil Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000021310 complex sugar Nutrition 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 230000000534 elicitor Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 150000002313 glycerolipids Chemical class 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 230000000174 oncolytic Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- DDBRXOJCLVGHLX-UHFFFAOYSA-O propane;trimethylazanium Chemical compound CCC.C[NH+](C)C DDBRXOJCLVGHLX-UHFFFAOYSA-O 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002441 reversible Effects 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 150000003712 vitamin E derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (38)
- 細胞に生物活性剤を送達するためのナノ構造脂質担体(NLC)粒子を含む組成物であって、
(a)液相脂質と固相脂質との混合物を含む油性コア、
(b)陽イオン性脂質を含む陽イオン性成分、
(c)ソルビタンエステルを含む疎水性界面活性剤、および
(d)親水性界面活性剤であって、前記陽イオン性成分に対するモル比が約0.2から約1.5である、親水性界面活性剤
(e)生物活性剤
を含む、前記NLC粒子。 - 前記生物活性剤が前記NLC粒子と結合している、請求項1に記載の組成物。
- 前記細胞に前記生物活性剤を送達する、請求項1または請求項2に記載の組成物。
- 前記疎水性界面活性剤がソルビタンエステルであり、ソルビタンエステルを含まない対照組成物と比較した場合に前記生物活性剤を前記細胞に送達する前記組成物の能力を増強するのに十分な量でソルビタンエステルが存在する、請求項1〜3のいずれか一項に記載の組成物。
- 前記生物活性剤がタンパク質であるか、前記生物活性剤がタンパク質をコードしているか、前記生物活性剤がタンパク質抗原であるか又は前記生物活性剤がタンパク質抗原をコードしている、請求項1〜4のいずれか一項に記載の組成物。
- 前記細胞が対象内の細胞であり、前記生物活性剤が抗原であり、前記組成物が前記抗原に対する前記対象の免疫応答を誘発させる、請求項1〜4のいずれか1項に記載の組成物。
- 前記対象に有効量で投与された場合に、前記生物活性剤を前記NLC無しで前記対象に投与した場合に誘発される免疫応答と同等以上の前記抗原に対する免疫応答を誘発させる、請求項1〜6のいずれか一項に記載の組成物。
- 前記生物活性剤がRNA、mRNA、腫瘍溶解性ウイルスRNAまたはDNAである、請求項1〜7のいずれか一項に記載の組成物。
- 前記液相脂質が代謝可能なものである、請求項1〜8のいずれか一項に記載の組成物。
- 前記液相脂質が植物油、動物油、または合成により作製された油である、請求項1〜9のいずれか一項に記載の組成物。
- 前記液相脂質が魚油である、請求項1〜10のいずれか一項に記載の組成物。
- 前記液相脂質がトリ(カプリル酸/カプリン酸)グリセリル、ビタミンE、ラウロイルポリオキシルグリセリド、モノアシルグリセロール、ダイズレシチン、スクアレン、もしくはスクアラン、またはこれらの組み合わせである、請求項1〜9のいずれか一項に記載の組成物。
- 前記液相脂質がスクアレン、ヒマワリ油、ダイズ油、オリーブ油、ブドウ種子油、スクアラン、トリ(カプリル酸/カプリン酸)グリセリル、またはこれらの組み合わせである、請求項1〜10のいずれか一項に記載の組成物。
- 前記液相脂質が天然テルペノイドまたは合成テルペノイドである、請求項1〜10のいずれか一項に記載の組成物。
- 前記液相脂質がスクアレンである、請求項12に記載の組成物。
- 前記固相脂質がグリセロ脂質である、請求項1〜15のいずれか一項に記載の組成物。
- 前記固相脂質が微結晶トリグリセリドである、請求項1〜15のいずれか一項に記載の組成物。
- 前記微結晶トリグリセリドがトリミリスチンである、請求項17に記載の組成物。
- 前記陽イオン性成分が、1,2−ジオレオイルオキシ−3−(トリメチルアンモニオ)プロパン(DOTAP)、3β−[N−(N′,N′−ジメチルアミノエタン)−カルバモイル]コレステロール(DCコレステロール)、ジメチルジオクタデシルアンモニウム(DDA)、1,2−ジミリストイル−3−トリメチルアンモニウムプロパン(DMTAP)、ジパルミトイル(C16:0)トリメチルアンモニウムプロパン(DPTAP)、ジステアロイルトリメチルアンモニウムプロパン(DSTAP)、N−[1−(2,3−ジオレイルオキシ)プロピル]−N,N,N−トリメチルアンモニウムクロリド(DOTMA)、N,N−ジオレオイル−N,N−ジメチルアンモニウムクロリド(DODAC)、1,2−ジオレオイル−sn−グリセロ−3−エチルホスホコリン(DOEPC)、1,2−ジオレオイル−3−ジメチルアンモニウム−プロパン(DODAP)、および1,2−ジリノレイルオキシ−3−ジメチルアミノプロパン(DLinDMA)、並びにこれらの組み合わせ、から選択される陽イオン性脂質である、請求項1〜18のいずれか一項に記載の組成物。
- 前記陽イオン性脂質が1,2−ジオレオイルオキシ−3−(トリメチルアンモニオ)プロパン(DOTAP)である、請求項19に記載の組成物。
- 前記親水性界面活性剤がポリエチレングリコールである、請求項1〜20のいずれか一項に記載の組成物。
- 前記親水性界面活性剤がポリオキシエチレンソルビタンエステルである、請求項21に記載の組成物。
- 前記ポリオキシエチレンソルビタンエステルが、ポリソルベート80である、請求項22記載の組成物。
- 前記NLC粒子の平均多分散指数が0.1〜約0.5である、請求項1〜23のいずれか一項に記載の組成物。
- 前記NLC粒子のz平均粒径が約20nm〜約200nm、約20nm〜約150、約20nm〜約100nm、約20nm〜約80nm、約20nm〜約60nm、約40nm〜約200nm、約40nm〜約150、約40nm〜約100nm、約40nm〜約80nm、または約40nm〜約60nmである、請求項1〜24のいずれか一項に記載の組成物。
- 前記疎水性界面活性剤が1〜5の親水性親油性バランス(HLB)値を有するソルビタンエステルである、請求項1〜25のいずれか一項に記載の組成物。
- 前記疎水性界面活性剤がソルビタンエステルであり、前記ソルビタンエステルがソルビタンモノエステルである、請求項1〜26のいずれか一項に記載の組成物。
- 前記疎水性界面活性剤がソルビタンエステルであり、前記ソルビタンエステルがソルビタンモノステアレート又はソルビタンモノオレートである、請求項1〜26のいずれか一項に記載の組成物。
- 前記NLC粒子のz平均粒径が約40nm〜約80nmである、請求項1〜28のいずれか一項に記載の組成物。
- 油:界面活性剤モル比が約0.05〜約12である、請求項1〜46のいずれか一項に記載の組成物。
- 親水性界面活性剤:陽イオン性成分比が約0.5〜約1である、請求項1〜30のいずれか一項に記載の組成物。
- 約0.2w/v%〜約40w/v%の液相脂質、約0.1w/v%〜約10w/v%の固相脂質、約0.2w/v%〜約10w/v%の陽イオン性脂質、約0.25w/v%〜約5w/v%のソルビタンモノエステル、および約0.5w/v%〜約10w/v%の親水性界面活性剤を含む、請求項1〜31のいずれか一項に記載の組成物。
- 前記油性コアが、スクアレン及びトリミリスチンを含み、前記陽イオン性脂質がDOTAPであり、前記ソルビタンエステルがソルビタンモノステアレートであり、前記親水性界面活性剤がポリソルベート80である、請求項1〜32のいずれか一項に記載の組成物。
- 対象において免疫応答を発生させる方法であって、それを必要とする対象に、治療有効量の請求項1〜33のいずれか一項に記載の組成物を投与することを含み、前記生物活性剤がタンパク質抗原またはタンパク質抗原をコードする核酸分子である、前記方法。
- 請求項1〜33のいずれか一項に記載の組成物を作製する方法であって、
(a)前記固相脂質と、前記液相脂質と、前記陽イオン性脂質と、前記疎水性界面活性剤とを混合して、油相混合物を形成させること;
(b)前記親水性界面活性剤と、水とを混合して、水相混合物を形成させること;
(c)前記油相混合物を前記水相混合物と混合して、前記NLC粒子を形成させること;および
(d)所望により、前記生物活性剤が非共有結合相互作用または可逆的共有結合相互作用によって前記NLC粒子の表面と結合するように、前記生物活性剤を前記NLC粒子と組み合わせること、
を含む、前記方法。 - 前記生物活性剤がRNAであり、前記RNAが1または複数のTB抗原をコードしている、請求項1〜33のいずれか一項に記載の組成物。
- アジュバントをさらに含む、請求項1〜33のいずれか一項に記載の組成物。
- 前記アジュバントがTLR作動薬、Rig−I作動薬、サポニン、糖、糖ポリマー、複合糖質、全ウイルス粒子、ウイルス様粒子、ウイルス断片、および細胞断片から選択される、請求項37に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024000126A JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Applications Claiming Priority (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762520204P | 2017-06-15 | 2017-06-15 | |
US62/520,204 | 2017-06-15 | ||
US201762540973P | 2017-08-03 | 2017-08-03 | |
US62/540,973 | 2017-08-03 | ||
US201762556291P | 2017-09-08 | 2017-09-08 | |
US62/556,291 | 2017-09-08 | ||
US201762563544P | 2017-09-26 | 2017-09-26 | |
US62/563,544 | 2017-09-26 | ||
US201762582859P | 2017-11-07 | 2017-11-07 | |
US62/582,859 | 2017-11-07 | ||
US201862622755P | 2018-01-26 | 2018-01-26 | |
US201862622748P | 2018-01-26 | 2018-01-26 | |
US62/622,755 | 2018-01-26 | ||
US62/622,748 | 2018-01-26 | ||
US201862669262P | 2018-05-09 | 2018-05-09 | |
US62/669,262 | 2018-05-09 | ||
US201862677336P | 2018-05-29 | 2018-05-29 | |
US62/677,336 | 2018-05-29 | ||
US201862680454P | 2018-06-04 | 2018-06-04 | |
US62/680,454 | 2018-06-04 | ||
PCT/US2018/037783 WO2018232257A1 (en) | 2017-06-15 | 2018-06-15 | Nanostructured lipid carriers and stable emulsions and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024000126A Division JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020524143A JP2020524143A (ja) | 2020-08-13 |
JP2020524143A5 true JP2020524143A5 (ja) | 2021-07-29 |
Family
ID=62948328
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019569758A Pending JP2020524143A (ja) | 2017-06-15 | 2018-06-15 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
JP2024000126A Pending JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024000126A Pending JP2024029173A (ja) | 2017-06-15 | 2024-01-04 | ナノ構造脂質担体、安定エマルジョン、およびその使用 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11141377B2 (ja) |
EP (1) | EP3638207A1 (ja) |
JP (2) | JP2020524143A (ja) |
KR (1) | KR20200028395A (ja) |
CN (1) | CN111315362A (ja) |
AU (1) | AU2018285694A1 (ja) |
BR (1) | BR112019026615B1 (ja) |
CA (1) | CA3067224A1 (ja) |
IL (1) | IL271384A (ja) |
MX (4) | MX2019015076A (ja) |
WO (1) | WO2018232257A1 (ja) |
ZA (1) | ZA201908207B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200028395A (ko) | 2017-06-15 | 2020-03-16 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
EP4058581A1 (en) | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
CA3169511A1 (en) * | 2020-02-26 | 2021-09-02 | Domenico FUOCO | Nanostructure lipid carrier delivery system, composition, and methods |
CN111494619B (zh) * | 2020-04-26 | 2022-03-18 | 南京农业大学 | 一种基于角鲨烯的阳离子纳米结构脂质载体免疫佐剂的制备方法 |
CA3174411A1 (en) * | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
CA3173951A1 (en) | 2020-09-04 | 2022-03-10 | Emily VOIGT | Genetically-adjuvanted rna vaccines |
CN117120087A (zh) | 2020-12-23 | 2023-11-24 | 高级健康研究所 | 茄尼醇疫苗助剂及其制备方法 |
WO2022251406A1 (en) * | 2021-05-28 | 2022-12-01 | The Regents Of The University Of Michigan | Combined agonist adjuvant for coronavirus vaccine |
CN117715929A (zh) | 2021-07-29 | 2024-03-15 | 南特细胞公司 | 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体 |
WO2023023332A1 (en) * | 2021-08-20 | 2023-02-23 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
AU2022349634A1 (en) * | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Nucleic acid sensor agonist compositions and uses thereof |
WO2023048759A1 (en) * | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Sars-cov-2 rna vaccine compositions and methods of use |
AU2022352486A1 (en) * | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
CA3232725A1 (en) * | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Cancer therapy compositions and uses thereof |
WO2023228116A1 (en) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Intranasal administration of thermostable rna vaccines |
KR20240033309A (ko) * | 2022-09-05 | 2024-03-12 | 주식회사 차백신연구소 | 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법 |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
AU626961B2 (en) | 1988-12-16 | 1992-08-13 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom |
DE69015222T2 (de) | 1989-02-04 | 1995-05-04 | Akzo Nv | Tocole als Impfstoffadjuvans. |
EP0414374B1 (en) | 1989-07-25 | 1997-10-08 | Smithkline Biologicals S.A. | Novel antigens and methods for their preparation |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
ATE332973T1 (de) | 1991-07-19 | 2006-08-15 | Univ Queensland | Polynukleotidabschnitt des hpv16-genoms |
KR100251505B1 (ko) | 1991-11-16 | 2000-05-01 | 장 스테판느 | 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag) |
DE122007000098I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
ATE296111T1 (de) | 1993-03-09 | 2005-06-15 | Univ Rochester | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6066324A (en) | 1994-10-07 | 2000-05-23 | Loyola University Of Chicago | Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles |
EP0812358A1 (en) | 1995-02-24 | 1997-12-17 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
ES2301178T3 (es) | 1996-04-05 | 2008-06-16 | Novartis Vaccines & Diagnostic | Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular. |
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
WO1998037418A2 (en) | 1997-02-25 | 1998-08-27 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and methods for their use |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
US6764686B2 (en) | 1997-07-21 | 2004-07-20 | Baxter International Inc. | Modified immunogenic pneumolysin compositions as vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
JP2002517179A (ja) | 1997-11-28 | 2002-06-18 | ジェンセット | Chlamydiatrachomatisゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用 |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
HU228467B1 (en) | 1998-02-05 | 2013-03-28 | Smithkline Beecham Biolog | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
TR200002938T2 (tr) | 1998-04-07 | 2001-02-21 | Corixa Corporation | Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı |
WO1999053061A2 (en) | 1998-04-15 | 1999-10-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
BR9912007A (pt) | 1998-07-14 | 2002-01-29 | Corixa Corp | Composições e métodos para terapia e diagnóstico de câncer de próstata |
PL203951B1 (pl) | 1999-04-19 | 2009-11-30 | Smithkline Beecham Biolog | Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie |
US6533949B1 (en) | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
DE60118228T2 (de) | 2000-09-28 | 2006-12-14 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Mikropartikel zur verabreichung von heterologen nukleinsäure |
CA2508228C (en) | 2002-12-23 | 2013-12-17 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US7998119B2 (en) | 2003-11-18 | 2011-08-16 | Nano Pass Technologies Ltd. | System and method for delivering fluid into flexible biological barrier |
AU2005248361B2 (en) | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
HUE037808T2 (hu) | 2006-09-26 | 2018-09-28 | Infectious Disease Res Inst | Szintetikus adalékanyagot tartalmazó vakcina kompozíció |
WO2008124647A2 (en) | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
US9421254B2 (en) * | 2007-09-24 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunostimulatory combinations of TLR ligands and methods of use |
BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
SG181904A1 (en) | 2009-12-23 | 2012-07-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
RU2649133C2 (ru) * | 2011-07-06 | 2018-03-29 | Новартис Аг | Катионные эмульсии масло-в-воде |
EP3424495A1 (en) * | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Oil-in-water emulsions that contain nucleic acids |
EP2729126B1 (en) * | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes having useful n:p ratio for delivery of rna molecules |
US10322089B2 (en) * | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
US8809388B2 (en) * | 2012-11-06 | 2014-08-19 | Brandeis University | Vegetable oil composition containing palm mid-fraction fat and method of reducing plasma cholesterol |
WO2014108515A1 (en) * | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
CA3024500A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
KR20200028395A (ko) * | 2017-06-15 | 2020-03-16 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
-
2018
- 2018-06-15 KR KR1020207001253A patent/KR20200028395A/ko active IP Right Grant
- 2018-06-15 MX MX2019015076A patent/MX2019015076A/es unknown
- 2018-06-15 EP EP18742621.8A patent/EP3638207A1/en active Pending
- 2018-06-15 AU AU2018285694A patent/AU2018285694A1/en active Pending
- 2018-06-15 BR BR112019026615-1A patent/BR112019026615B1/pt active IP Right Grant
- 2018-06-15 CN CN201880050697.XA patent/CN111315362A/zh active Pending
- 2018-06-15 US US16/622,908 patent/US11141377B2/en active Active
- 2018-06-15 WO PCT/US2018/037783 patent/WO2018232257A1/en active Application Filing
- 2018-06-15 CA CA3067224A patent/CA3067224A1/en active Pending
- 2018-06-15 JP JP2019569758A patent/JP2020524143A/ja active Pending
-
2019
- 2019-12-10 ZA ZA2019/08207A patent/ZA201908207B/en unknown
- 2019-12-12 IL IL271384A patent/IL271384A/en unknown
- 2019-12-13 MX MX2022013320A patent/MX2022013320A/es unknown
- 2019-12-13 MX MX2022013322A patent/MX2022013322A/es unknown
- 2019-12-13 MX MX2023006661A patent/MX2023006661A/es unknown
-
2021
- 2021-09-09 US US17/470,874 patent/US20220054416A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000126A patent/JP2024029173A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020524143A5 (ja) | ||
Pilkington et al. | From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases | |
JP6505912B2 (ja) | 改良されたアミノ脂質および核酸の送達方法 | |
Chatzikleanthous et al. | Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines | |
JP7333563B2 (ja) | 脂質ナノ粒子 | |
Perrie et al. | Liposome-mediated DNA vaccination: the effect of vesicle composition | |
Davidsen et al. | Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses | |
Watson et al. | Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens | |
US20170049702A1 (en) | Method to Enhance an Immune Response of Nucleic Acid Vaccination | |
JP2013531680A5 (ja) | ||
CN111315362A (zh) | 纳米结构脂质载剂和稳定乳剂以及其用途 | |
DK2729127T3 (en) | METHODS FOR LIPOSOMES PREPARATION | |
RU2014104092A (ru) | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты | |
EP1765289B1 (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
US20110177156A1 (en) | Sterol-Modified Amphiphilic Lipids | |
Nordly et al. | Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo | |
JP2014522840A5 (ja) | ||
Paecharoenchai et al. | Structure relationship of cationic lipids on gene transfection mediated by cationic liposomes | |
KR20220156933A (ko) | Rna의 전달을 위한 조성물 및 방법 | |
EP3147277B1 (en) | Lipid membrane structure for sirna intracellular delivery | |
Perrie et al. | Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route | |
WO2017102703A1 (en) | Vaccine | |
Wölk et al. | Investigation of binary lipid mixtures of a three-chain cationic lipid with phospholipids suitable for gene delivery | |
JP5390059B2 (ja) | 無菌ポリヌクレオチド系薬剤の製造方法 | |
JP7082110B2 (ja) | アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット |